# Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Source: https://onco.cc/trials/nct07343479/  
OnCo record `nct07343479` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab tirumotecan in lung cancer, run by Zhejiang Cancer Hospital, not yet recruiting.

## Summary

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases is a phase 2, interventional study registered as NCT07343479 by Zhejiang Cancer Hospital, with a registry enrolment figure of 45 participants, started 2026-05-01 and due to reach its primary completion in 2027-06-20. Interventions recorded: sac-TMT plus EGFR-TKI. Conditions listed: NSCLC (Advanced Non-small Cell Lung Cancer); EGFR Gene Mutations; Brain Metastasis. Primary outcome: 6-month PFS rate. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed non-squamous NSCLC, and metastatic (Stage IV);". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07343479
- Phase: 2
- Setting: A Clinical Study of Sac-TMT for Injection Combined With Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) ± Radiotherapy in Subjects With EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer and Brain Metastasis Who Have Failed Prior EGFR-TKI Treatment
- Sponsor: Zhejiang Cancer Hospital
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT07343479: https://clinicaltrials.gov/study/NCT07343479

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07343479.json